Bone Mineral Density Changes Among Women Initiating Proton Pump Inhibitors or H2 Receptor Antagonists: A SWAN Cohort Study
Open Access
- 22 August 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 30 (2) , 232-239
Abstract
: Proton pump inhibitors (PPIs) have been associated with diminished bone mineral density (BMD) and an increased risk of fracture; however, prior studies have not yielded consistent results, and many have suboptimal ascertainment of both PPI use and BMD. We used data from the Study of Women's Health Across the Nation (SWAN), a multicenter, multi-ethnic, community-based longitudinal cohort study of women across the menopause transition to examine the association between annualized BMD changes and new use of PPIs. We compared changes in BMD in new PPI users with changes in BMD in new users of histamine 2 receptor antagonists (H2RAs) and with changes in BMD in subjects who did not use either class of medications. Mixed linear regression models included recognized risk factors for osteoporosis, including demographics, menopausal transition stage, body mass index (BMI), lifestyle factors, as well as comorbidities and concomitant medications. To provide further evidence for the validity of our analytic approach, we also examined the effects of hormone-replacement therapy (HT), a class of medications that should reduce bone loss, on changes in BMD as an internal positive control group. We identified 207 new users of PPIs, 185 new users of H2RAs, and 1,676 non-users. Study subjects had a mean age of 50 years and were followed for a median of 9.9 years. Adjusted models found no difference in the annualized BMD change at the lumbar spine, femoral neck, or total hip in PPI users compared with H2RA users or non-users. These results were robust to sensitivity analyses. BMD increased as expected in HT users, supporting the validity of our study design. These longitudinal analyses plus similar prior studies argue against an association between PPI use and BMD loss. © 2014 American Society for Bone and Mineral Research.Keywords
Funding Information
- NIH Office of Research on Women's Health (ORWH) (NR004061, AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495)
This publication has 25 references indexed in Scilit:
- Risk Factors for Falls with Use of Acid-Suppressive DrugsEpidemiology, 2013
- Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: Results from the Study of Women's Health Across the Nation (SWAN)Journal of Bone and Mineral Research, 2011
- Proton Pump Inhibitors and Risk of Fractures: A Meta-Analysis of 11 International StudiesThe American Journal of Medicine, 2011
- Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk PatientsGastroenterology, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older AdultsCalcified Tissue International, 2008
- Use of proton pump inhibitors and risk of osteoporosis-related fracturesCanadian Medical Association Journal, 2008
- Osteoimmunology: Interactions of the Bone and Immune SystemEndocrine Reviews, 2008
- Bone Mineral Density Changes during the Menopause Transition in a Multiethnic Cohort of WomenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Physical Activity Patterns in a Diverse Population of WomenPreventive Medicine, 1999